Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Trials

Lambert-Eaton Myasthenic Syndrome results from autoantibodies against voltage-gated calcium channels (VGCCs) at the presynaptic terminal of the neuromuscular junction. These antibodies prevent calcium influx necessary for acetylcholine release, leading to inefficient neuromuscular transmission. Most LEMS patients (80-85%) are seropositive for anti-VGCC antibodies, and the rest are called seronegative.

The most common symptoms of Lambert-Eaton Myasthenic Syndrome include Progressive weakness of legs and sometimes arms, Leg fatigue and difficulty climbing stairs, Diminished or absent deep tendon reflexes, Autonomic symptoms including dry mouth and constipation, Ptosis and diplopia in some patients, among others. About 2.3 per million people in a Dutch population study, with about 0.48 new cases per million people a year (Wirtz et al., J Neurol 2003); about half of patients have an underlying cancer, usually small cell lung cancer (Titulaer et al., Lancet Neurol 2011). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Lambert-Eaton Myasthenic Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Treatment for Lambert-Eaton Myasthenic Syndrome combines symptomatic approaches that enhance neuromuscular transmission with immunomodulatory therapies addressing the underlying autoimmune cause. Potassium channel blockers improve muscle strength by enhancing acetylcholine release, while immunotherapy targets the antibodies attacking calcium channels.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Lambert-Eaton Myasthenic Syndrome: Firdapse (amifampridine phosphate). Corticosteroids and immune globulins count once each.

The exact cause of Lambert-Eaton Myasthenic Syndrome is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune (anti-VGCC antibodies), often paraneoplastic with small cell lung cancer; HLA associations only, no gene test. About 2.3 per million people in a Dutch population study, with about 0.48 new cases per million people a year (Wirtz et al., J Neurol 2003); about half of patients have an underlying cancer, usually small cell lung cancer (Titulaer et al., Lancet Neurol 2011). Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Lambert-Eaton Myasthenic Syndrome. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune (anti-VGCC antibodies), often paraneoplastic with small cell lung cancer; HLA associations only, no gene test.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Lambert-Eaton Myasthenic Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Lambert-Eaton Myasthenic Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.